AC Immune has reduced its workforce by about 30% and streamlined its pipeline, focusing resources on late-stage therapies.
The strategic move is intended to extend AC Immune’s cash runway into the third quarter of 2027, with CHF 127.1 million in cash as of June 30, 2025.13
The company is now concentrating on advancing active immunotherapies for Alzheimer’s and Parkinson’s diseases, as well as targeting novel intracellular mechanisms.13
Severance packages and job search support will be provided to affected employees.1
Interim clinical data readouts for main programs (ACI-7104.056 and ACI-24.060) are expected in the second half of 2025 and first half of 2026, respectively.1
The move puts AC Immune among the largest biopharma layoffs reported in the first half of 2025.5
Sources:
1. https://www.quiverquant.com/news/AC+Immune+SA+Announces+Strategic+Pipeline+Focus+and+Workforce+Reduction+to+Extend+Cash+Runway
3. https://firstwordpharma.com/story/5994615
5. https://www.biospace.com/job-trends/the-5-largest-biopharma-layoffs-of-h1-2025